FDA Issues Safety Notice Increased Risk of Bladder Cancer Linked to Actos
Actos Bladder Cancer Injury Attorneys in Indiana
The FDA recently issued an updated safety notice related to an increased risk for bladder cancer for patients taking Actos and other pioglitazone-containing medicines including Actoplus Met, Actoplus Met XR, Duetact, and Oseni. The initial safety notice was based off interim results from a 10-year study to assess the risks for bladder cancer associated with use of Actos and similar drugs. This new safety notice includes an approved label update about an increased risk for bladder cancer after additional studies were reviewed.
The new safety notice warns patients to contact their healthcare provider if they experience blood or a red color in the urine, new or worsening urge to urinate, or pain when urinating as these may all be symptoms of bladder cancer. It also warns health care professionals to not prescribe Actos and other pioglitazone-containing drugs to patients who currently have bladder cancer or a history of bladder cancer.
If you or someone you know has been prescribed Actos, Actoplus Met, Actoplus Met XR, Duetact, or Oseni and has been diagnosed with bladder cancer, contact us. Our product liability attorneys have litigated thousands of cases against pharmaceutical manufacturers and can provide you with a free case evaluation and advise you of your legal rights and options.
